The Proteomic Profile of Keratinocytes and Lymphocytes in Psoriatic Patients.


Journal

Proteomics. Clinical applications
ISSN: 1862-8354
Titre abrégé: Proteomics Clin Appl
Pays: Germany
ID NLM: 101298608

Informations de publication

Date de publication:
07 2019
Historique:
received: 10 07 2018
revised: 04 12 2018
pubmed: 17 1 2019
medline: 25 1 2020
entrez: 17 1 2019
Statut: ppublish

Résumé

Psoriatic skin lesions are associated with chronic inflammation related to immune cell activity. Therefore, the aim of this study is to compare changes in the proteome of psoriatic keratinocytes and lymphocytes. A proteomics approach is used to analyze the expression of proteins in keratinocytes and lymphocytes from psoriatic patients and healthy controls. As a result 2119 proteins for keratinocytes and 1235 proteins for lymphocytes are identified. Psoriatic keratinocytes has 68 downregulated and 7 upregulated proteins and psoriatic lymphocytes has 106 downregulated and 67 upregulated proteins compared to healthy individuals. The list of downregulated proteins includes proteins involved in antioxidant homeostasis and, transcription regulation; upregulated proteins are involved in glycolytic processes and translation. These changes are accompanied by an increased level of 4-Hydroxynonenal-protein adducts; control cells are characterized by 4-Hydroxynonenal-Lysine adducts formed with structural and binding proteins, while in psoriatic cells 4-Hydroxynonenal-Lysine, 4-Hydroxynonenal-Histidine, and 4-Hydroxynonenal-Cysteine adducts with various molecular function proteins occur. This study highlights the changes in psoriatic keratinocytes and lymphocytes that can be directly involved in the development of psoriasis. In both cell types the most significant changes are associated with upregulation of phosphoglycerate mutase 1 and downregulation of thioredoxin reductase.

Identifiants

pubmed: 30648813
doi: 10.1002/prca.201800119
doi:

Substances chimiques

Proteome 0
Thioredoxin-Disulfide Reductase EC 1.8.1.9
Phosphoglycerate Mutase EC 5.4.2.11
phosphoglycerate mutase 1, human EC 5.4.2.11

Types de publication

Clinical Trial Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1800119

Informations de copyright

© 2019 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Auteurs

Agnieszka Gęgotek (A)

Department of Analytical Chemistry, Medical University of Bialystok, 15-089, Bialystok, Poland.

Pedro Domingues (P)

Mass Spectrometry Center, QOPNA, Department of Chemistry, University of Aveiro, 3810-193, Aveiro, Portugal.

Adam Wroński (A)

Dermatological Specialized Center "DERMAL" NZOZ in Bialystok, 15-453, Bialystok, Poland.

Ewa Ambrożewicz (E)

Department of Analytical Chemistry, Medical University of Bialystok, 15-089, Bialystok, Poland.

Elżbieta Skrzydlewska (E)

Department of Analytical Chemistry, Medical University of Bialystok, 15-089, Bialystok, Poland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH